EMA Authorised: Nexavar (sorafenib) — Bayer AG

View source ↗

Summary

The EMA authorised Nexavar (sorafenib) for hepatocellular carcinoma and renal cell carcinoma. The decision date was 13 February 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Hepatocellular;Carcinoma, Renal Cell. MAH: Bayer AG. Decision date: 13/02/2025